Neddie Zadeikis

ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study.

A. Wald, S. Tyring, S. Dhadda, 2012, Journal of Infectious Diseases.

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older

T. Asselah, G. Foster, F. Mensa, 2019, PloS one.

ASP 2151 for the Treatment of Genital Herpes : A Randomized , Double-Blind , Placebo-and Valacyclovir-Controlled , Dose-Finding Study

A. Wald, S. Tyring, S. Dhadda, 2012 .

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.

T. Asselah, S. Lim, E. Gane, 2019, The lancet. Gastroenterology & hepatology.

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

V. de Lédinghen, R. Marinho, T. Asselah, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid‐Reducing Agents in Patients With Chronic HCV Infection

K. Reddy, T. Hassanein, B. Bacon, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

ENDURANCE-4: Efficacy and Safety of ABT-493/ABT-530 Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection

R. Marinho, T. Asselah, F. Nevens, 2016 .

The 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016.

M. Colombo, W. Rosenberg, G. Foster, 2016, Hepatology.

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

C. Stedman, T. Pilot‐Matias, A. Tran, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Analysis of AST to Platelet Ratio Index (APRI) for Determining Eligibility for 8 Weeks of Glecaprevir/Pibrentasvir

R. Fontana, T. Asselah, F. Mensa, 2018, American Journal of Gastroenterology.

Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection: an integrated analysis

O. Weiland, J. Dufour, S. Paik, 2017 .

Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects

S. Dutta, J. Kort, T. Podsadecki, 2017, Journal of clinical pharmacology.

ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study.

A. Wald, S. Tyring, S. Dhadda, 2012, The Journal of infectious diseases.